---
title: "AbbVie Inc. Stock Underperforms Tuesday When Compared To Competitors Despite Daily Gains"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289234340.md"
description: "AbbVie Inc. (ABBV) shares rose 1.05% to $225.42 on Tuesday, underperforming competitors like Johnson & Johnson and Pfizer despite the daily gain. The stock closed 7.92% below its 52-week high of $244.81. Trading volume was lower than the 50-day average."
datetime: "2026-06-09T20:31:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289234340.md)
  - [en](https://longbridge.com/en/news/289234340.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289234340.md)
---

# AbbVie Inc. Stock Underperforms Tuesday When Compared To Competitors Despite Daily Gains

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of AbbVie Inc. (ABBV) rose 1.05% to $225.42 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average rising 0.17% to 50,872.11 and the S&P 500 Index falling 0.26% to 7,386.65.

AbbVie Inc. closed 7.92% below its 52-week high of $244.81, which the company achieved on October 1st.

The stock demonstrated a mixed performance when compared to some of its competitors Tuesday, as Johnson & Johnson (JNJ) rose 2.08% to $237.00, Pfizer Inc. (PFE) rose 0.31% to $25.70, and Amgen Inc. (AMGN) fell 0.34% to $344.57.

Trading volume (4.1 M) remained 2.2 million below its 50-day average volume of 6.2 M.

Data source: Dow Jones Market Data, FactSet. Data compiled June 9, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

06-09-26 1631ET

### Related Stocks

- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)
- [.DJI.US](https://longbridge.com/en/quote/.DJI.US.md)
- [.SPX.US](https://longbridge.com/en/quote/.SPX.US.md)
- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)
- [PFE.US](https://longbridge.com/en/quote/PFE.US.md)
- [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md)

## Related News & Research

- [Is AbbVie the Most Underrated Dividend Growth Stock in the S&P 500?](https://longbridge.com/en/news/289009743.md)
- [AbbVie Delivers Strong Q1 Earnings Beyond Humira. This Dividend King Still Shines.](https://longbridge.com/en/news/285600926.md)
- [AbbVie Touts Record Sales and Pipeline Momentum at Annual Meeting](https://longbridge.com/en/news/285815191.md)
- [FACTBOX-Major deals involving US drugmakers and biotechs over the past decade](https://longbridge.com/en/news/289163903.md)
- [AbbVie beats earnings estimates, boosts 2026 outlook. What it means for the stock.](https://longbridge.com/en/news/284576830.md)